Prognostic factors of renal cell carcinoma

被引:85
作者
Méjean, A
Oudard, S
Thiounn, N
机构
[1] Hop Europeen Georges Pompidou, Hop Necker Enfants Malades, Serv Urol, Paris, France
[2] Hop Europeen Georges Pompidou, Serv Oncol, Paris, France
关键词
prognosis; carcinoma; renal cell; disease management; multivariate analysis; kidney;
D O I
10.1097/01.ju.0000051378.14270.2a
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Determination of prognostic factors is essential for the management of renal cell carcinoma. Stage, histological grade and type, and performance status are now well known and commonly used. During the last decade numerous predictors of patient outcome were tested. This review summarizes the most important studies, explores and compares the results, and tries to respond to the question, "Today, what do we expect of clinical, molecular and genetic factors concerning survival of patients with renal cell carcinoma?" Materials and Methods: Based on MEDLINE literature searches we comprehensively reviewed the literature on the prognotic factors associated with the tumor, the patient and the treatment. Results: During the last decades numerous factors have been studied but few of them maintained independent significance in terms of overall survival as assessed by multivariate analysis. Results are more often controversial from one series to another. No known molecular or cytogenetic tumor marker has been identified to help diagnose, manage or confirm renal cell carcinoma remission, progression or relapse. Conclusions: The classical prognostic factors remain histological grade, histological type, performance status, patient age, number and location(s) of metastatic sites, time to appearance of metastases and prior nephrectomy. The only striking advancement during the last few years has been the proven contribution of radical nephrectomy for metastatic disease in patients with good performance status.
引用
收藏
页码:821 / 827
页数:7
相关论文
共 117 条
[81]   Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil [J].
Négrier, S ;
Caty, A ;
Lesimple, T ;
Douillard, JY ;
Escudier, B ;
Rossi, JF ;
Viens, P ;
Gomez, F .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (24) :4009-4015
[82]  
Onishi T, 1999, BJU INT, V83, P937
[83]  
Oudard S, 2002, ANTICANCER RES, V22, P121
[84]   PROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA TREATED WITH RECOMBINANT INTERLEUKIN-2 [J].
PALMER, PA ;
VINKE, J ;
PHILIP, T ;
NEGRIER, S ;
ATZOPODIEN, J ;
KIRCHNER, H ;
OSKAM, R ;
FRANKS, CR .
ANNALS OF ONCOLOGY, 1992, 3 (06) :475-480
[85]   CD44 is an independent prognostic factor in conventional renal cell carcinomas [J].
Paradis, V ;
Ferlicot, S ;
Ghannam, E ;
Zeimoura, L ;
Blanchet, P ;
Eschwége, P ;
Jardin, A ;
Benoît, G ;
Bedossa, P .
JOURNAL OF UROLOGY, 1999, 161 (06) :1984-1987
[86]   RENAL-CELL CARCINOMA - RESECTION OF SOLITARY AND MULTIPLE METASTASES [J].
POGREBNIAK, HW ;
HAAS, G ;
LINEHAN, WM ;
ROSENBERG, SA ;
PASS, HI ;
PUTNAM, JB ;
MANSOUR, KA ;
COOK, WA .
ANNALS OF THORACIC SURGERY, 1992, 54 (01) :33-38
[87]   Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer [J].
Pyrhönen, S ;
Salminen, E ;
Ruutu, M ;
Lehtonen, T ;
Nurmi, M ;
Tammela, T ;
Juusela, H ;
Rintala, E ;
Hietanen, P ;
Kellokumpu-Lehtinen, PL .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2859-2867
[88]   Serum beta(2)-microglobulin and prognosis of patients with renal cell carcinoma [J].
Rasmuson, T ;
Grankvist, K ;
Ljungberg, B .
ACTA ONCOLOGICA, 1996, 35 (04) :479-482
[89]  
RASMUSON T, 1993, CANCER, V72, P1324, DOI 10.1002/1097-0142(19930815)72:4<1324::AID-CNCR2820720429>3.0.CO
[90]  
2-W